A phase I open-label, non-randomized, dose-finding safety, tolerance and pharmacokinetic study of TSU-68 in combination with S-1 and oxaliplatin in patients with metastatic colorectal cancer.
Latest Information Update: 03 Jun 2016
At a glance
- Drugs Orantinib (Primary) ; Gimeracil/oteracil/tegafur; Oxaliplatin
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Taiho Pharmaceutical
- 03 Jun 2016 New trial record